+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 217 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating a new imaging method called 4FMFES-PET combined with FDG-PET to improve diagnosis and management of advanced estrogen receptor-positive ER breast cancer. ER status is a key factor in guiding treatment choices, but tumors can vary in ER expression over time and across sites. This study aims to assess the full potential of 4FMFES-PET, which has shown better image quality and tumor detection than earlier tracers, in combination with FDG-PET for whole-body, non-invasive ER status evaluation in advanced breast cancer patients. Participants with advanced ER breast cancer will undergo 4FMFES-PET imaging at the start, then again at 6 and 18 months, within 4 weeks of medically prescribed FDG-PET scans. The 4FMFES tracer is given intravenously followed by PET imaging. The study will compare and complement these PET scans with conventional imaging and correlate imaging results with pathology from biopsies and with clinical outcomes like treatment response and progression-free survival. During the study, participants will have multiple PET scans to monitor ER expression and tumor activity over time. Researchers will collect pathological data and track outcomes such as time to recurrence and treatment effects. The main measurements include uptake of 4FMFES on PET scans correlated with tissue markers and clinical progress over 18 to 36 months. This approach aims to better identify patient groups who may benefit from this imaging method to guide their care.

Age: 18Years +All GendersPhase 2
1 location
P

Actively Recruiting

Neuroblastoma is the most common extracranial tumor in children, occurring at a rate of about 10.2 cases per million yearly. This study is a phase II pilot trial designed to assess the use of a new imaging method, 68Ga-DOTATATE PETCT, for detecting neuroblastoma and compare it to the existing 123I-MIBG scan. Researchers aim to evaluate the feasibility and safety of 68Ga-DOTATATE and how accurately it identifies neuroblastoma lesions compared to 123I-MIBG. Participants will first undergo a 123I-MIBG scan followed by a 68Ga-DOTATATE PETCT scan a few days later. The 68Ga-DOTATATE is a radiopharmaceutical injected into the patient, and imaging is done approximately one hour post-injection, lasting about two hours. This single-arm study includes children and young adults up to 21 years old who have biopsy-proven or suspected neuroblastoma. The study monitors adverse events within 24 hours after the 68Ga-DOTATATE injection. During the study, researchers will collect clinical data from the imaging scans and participants medical records for up to two years, including demographics, treatments, medications, pathology, and laboratory tests. Outcome measurements focus on the rate of participant enrollment and any side effects from the 68Ga-DOTATATE injection, as well as lesion detection and differences between the two imaging methods. Participants health status will be followed regularly to assess the imaging techniques effectiveness and safety.

Age: 0 - 21YearsAll GendersPhase 2
3 locations
S

Actively Recruiting

Researchers are evaluating the safety and clinical usefulness of cyclotron-produced 68Ga-PSMA-617 PET imaging in cancers that express PSMA, including prostate cancers and many other solid tumors. This open-label, non-randomized study aims to gather information on how this imaging method impacts patient management compared to current standard care. The study also seeks to promote routine use of this PET imaging in clinical settings for eligible cancer patients. Participants will receive an intravenous injection of 68Ga-PSMA-617, with the dose adjusted based on patient weight and PET scanner characteristics, up to a maximum of 370 MBq. About 60 to 90 minutes after the injection, they will undergo PETCT scanning to capture images of their tumors. These images will be reviewed by a nuclear medicine physician. The study will monitor safety, including any side effects, and assess the accuracy of the imaging by identifying false positives or negatives and unusual tracer distribution. During the study, participants will be involved in the injection and imaging procedures, followed by monitoring for adverse events and analysis of imaging results. Researchers will collect data on how the imaging influences cancer staging, treatment decisions, and follow-up care. The main outcome measured is the incidence of treatment-emergent adverse events over five years. Additional outcomes include evaluating the impact on patient management and encouraging the adoption of 68Ga-PSMA-617 PETCT as a standard diagnostic tool.

All AgesAll Genders
1 location
E

Actively Recruiting

This research aims to evaluate the efficacy and safety of rilzabrutinib in adults diagnosed with active Immunoglobulin G4-related disease IgG4-RD. It is a Phase 3, randomized, double-blind, placebo-controlled study that will measure the time to clinical disease flare and other important efficacy and safety outcomes over a 52-week treatment period. The study includes adult participants aged 18 and older who have a confirmed diagnosis of IgG4-RD and active disease in at least one organ. Participants will be randomly assigned to receive either rilzabrutinib tablets or a placebo, both taken orally, over a 52-week double-blind treatment period. The study also includes a screening period of 4 to 6 weeks before treatment, followed by a 2-week follow-up after the treatment phase. An optional open-label extension lasting 108 weeks is available for participants who complete the main study. The total study duration may extend up to 60 weeks for the main phases. Throughout the study, participants will attend up to 16 visits during the main treatment period and additional visits if they join the extension phase. Researchers will monitor disease activity and flare rates using clinical assessments, imaging procedures such as CT, MRI, PET, or ultrasound, laboratory tests, ECGs, and safety evaluations including adverse event monitoring. Outcomes include flare-free rates, disease activity scores, glucocorticoid use, and safety parameters, with follow-up continuing beyond the treatment phase to assess long-term effects.

Age: 18Years +All GendersPhase 3
95 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of ifinatamab deruxtecan I-DXd, alone or combined with other treatments, in people with metastatic castration-resistant prostate cancer mCRPC. This study aims to understand how well participants tolerate the treatment, find a safe dose level for combination therapies, and monitor prostate-specific antigen PSA levels during treatment. The study is part of a larger master screening protocol and includes participants with advanced prostate cancer. Participants may receive one of several treatment plans docetaxel chemotherapy every three weeks for up to 10 cycles I-DXd alone every three weeks until side effects, disease progression, death, or withdrawal I-DXd combined with opevesostat after dose escalation until stopping criteria are met or I-DXd combined with an androgen receptor pathway inhibitor abiraterone or enzalutamide under similar conditions. Before each I-DXd dose, participants take medications to prevent nausea and vomiting. During the study, participants will have regular assessments including monitoring for treatment side effects, PSA response, and disease progression. Researchers will track dose-limiting toxicities, adverse events, and reasons for stopping treatment over periods ranging from about three weeks to over four years. Secondary measures include overall survival, radiographic progression-free survival, and time to pain progression. Participation may last several years, with ongoing safety and effectiveness evaluations carried out throughout this time.

Age: 18Years +All GendersPhase 1Phase 2
82 locations
E

Actively Recruiting

Researchers are investigating new treatments for people with high-risk non-muscle invasive bladder cancer HR NMIBC, a type of bladder cancer that affects the inner lining and has not spread to the muscle. This condition includes carcinoma in situ CIS, a flat cancer limited to the bladders surface. The study aims to find out if adding intismeran autogene to the standard Bacillus Calmette-Guerin BCG treatment can help patients live longer without their cancer growing, spreading, or returning. Participants receive either intismeran autogene combined with BCG or BCG alone. Intismeran autogene is given as a 1 mg intramuscular injection every 3 weeks for nine doses. BCG is administered as a 50 mg intravesicular instillation once weekly for 6 weeks initially, then during weeks 13-15, 25-27, 49-51, and 73-75. Some participants receive only intismeran autogene. The study follows these treatments in separate groups to compare outcomes. During the study, participants undergo assessments over up to approximately five years to measure event-free survival, recurrence-free survival, disease-specific survival, overall survival, and other health outcomes. Researchers track cancer response, monitor adverse events, and evaluate how long participants remain cancer-free. Regular visits and tests help monitor safety and treatment effects throughout the study period.

Age: 18Years +All GendersPhase 2
89 locations
E

Actively Recruiting

Researchers are evaluating new treatment options for metastatic cervical cancer, a condition where cancer has spread from the cervix to other parts of the body. This study focuses on the safety and effectiveness of combining sacituzumab tirumotecan sac-TMT, pembrolizumab, and bevacizumab, compared to standard treatments. The research aims to understand how well these medicines work together and whether they help people live longer or delay cancer progression. The study has two parts. In Part 1, eligible participants receive sac-TMT with pembrolizumab and bevacizumab to assess safety. In Part 2, all participants first undergo standard induction treatment with pembrolizumab, paclitaxel, and cisplatin or carboplatin, with optional bevacizumab. Those whose cancer does not worsen are randomized to receive either pembrolizumab alone or sac-TMT plus pembrolizumab, with optional bevacizumab for maintenance treatment. Treatments are given by intravenous infusion at specified doses and schedules over several months. Participants will be closely monitored throughout the study with regular visits to assess safety, cancer progression, and quality of life. Researchers will track adverse events, treatment tolerability, progression-free survival, and overall survival. Quality of life questionnaires and physical functioning assessments are included to understand the impact of treatment. The study duration may extend up to approximately 69 months for safety follow-up, with various outcome measures evaluated at set intervals.

Age: 18Years +FEMALEPhase 3
191 locations
E

Actively Recruiting

Researchers are studying the safety and tolerability of Sacituzumab Tirumotecan when given directly into the bladder in people with intermediate-risk non-muscle invasive bladder cancer NMIBC. This phase 12 open-label study aims to find the highest dose participants can take without significant problems and to select a dose for future studies to evaluate how well the drug works. Participants will receive intravesical Sacituzumab Tirumotecan once a week for six weeks. The study may also include the use of rescue medications and supportive care measures to manage side effects. The study is designed as a single group where all participants receive the experimental treatment. During the study, participants will be closely monitored for dose-limiting toxicities and adverse events, with safety assessments over approximately 6 to 10 weeks. Researchers will also measure drug levels in the blood and evaluate treatment response up to 24 months. The total participation duration can be up to two years for some outcome measures.

Age: 18Years +All GendersPhase 1Phase 2
13 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations

1-10 of 217

1